BILAG

AcronymDefinition
BILAGBritish Isles Lupus Assessment Group
BILAGBritish Isles Lupus Activity Group
References in periodicals archive ?
RCI led to significant improvement in secondary efficacy endpoints compared with placebo, including reduction in total hSLEDAI, BILAG, and CLASI Activity scores, decreased tender and swollen joint count, and increased proportion of subjects achieving response as defined by SRI.
30 points or more from baseline); and (3) no new BILAG A organ domain score (which indicates a severe flare of lupus disease activity) and no more than one new BILAG B organ domain score (which would indicate a moderate flare of disease activity).
The article concluded that the favorable safety profile and encouraging clinically significant effects noted in some of the endpoints support the need for additional longer term Edratide studies that incorporate recent advances in the understanding and treatment of SLE, including steroid treatment algorithms, and using a composite primary endpoint which is likely to include BILAG.
A decrease from 23% to 11% in the frequency of patients experiencing a new BILAG A flare (which would indicate a severe flare of lupus disease activity) or more than one new BILAG B flare (which would indicate a moderate flare of disease activity).
There was no difference in the percentage of patients who experienced flare, as defined by BILAG, over the course of 52 weeks.
The SRI defines patient response as an improvement in SELENA SLEDAI score of 4 points or greater, with no clinically significant BILAG worsening and no clinically significant worsening in Physician's Global Assessment.
Isenberg was one of the creators of the BILAG index, one of the endpoints currently recommended by the FDA, while Dr.
15,18-20) In addition to work being performed in clinics by international groups, such as the SLICC (Systemic Lupus International Collaborating Clinics), the EULAR (European League Against Rheumatism) group, and a group chartered by the Lupus Foundation of America [which is working to optimize flare measurements and using both the SLEDAI (Systemic Lupus Erythematosus Disease Activity Index) and the BILAG (British Isles Lupus Assessment Group) instruments], data from recent industry-sponsored clinical trials support increased understanding of the strengths and weaknesses of each outcome measure.
There were also significant improvements noted in patients' BILAG scores, a clinical measurement of Lupus disease activity.
The SLE Responder Index defines patient response as an improvement in SELENA SLEDAI score of 4 points or greater, with no clinically significant BILAG worsening and no clinically significant worsening in Physician's Global Assessment.
The BLISS-52 patient response rate was based on the SLE Responder Index (SRI), which defines patient response by an improvement in SELENA SLEDAI score of 4 points or greater, with no clinically significant BILAG worsening, and no clinically significant worsening in Physician's Global Assessment.
However, the PRELUDE trial showed encouraging results in its secondary clinical endpoint, the BILAG index, and, in fact, the 0.